Industry Overview

Brachytherapy market was valued at $1.7 billion in 2025 and is projected to reach $3.2 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). The market is growing due to the increasing incidence of cancer, especially in aging populations, and advancements in minimally invasive, precise treatment methods. Key factors driving growth include technological innovation, rising healthcare expenditure in emerging economies, government initiatives for cancer research, and the higher cure rates and cost-effectiveness offered by brachytherapy compared to traditional surgery or external beam therapy.

Market Dynamics

Rising Global Cancer Prevalence and Increasing Preference for Localized Radiation Therapy

One of the primary forces driving the brachytherapy market is the increasing global burden of cancer, particularly prostate, breast, cervical and skin cancers where brachytherapy is widely recognised as a gold-standard or highly recommended treatment modality. The growing demand for organ-preserving and localized radiation therapy supports brachytherapy adoption because the technique delivers a high radiation dose directly to the tumour with minimal damage to surrounding healthy tissues. As early diagnosis rates improve and patient awareness about minimally invasive treatment options rises, hospitals and oncology centres continue to increase their utilisation of high-dose-rate (HDR), low-dose-rate (LDR) and electronic brachytherapy to support better clinical outcomes and shorter treatment duration.

Technological Advancements in Imaging, Treatment-Planning, and Applicators

Rapid innovation in brachytherapy technology is another major contributor to market growth. The integration of CT, MRI and ultrasound imaging with treatment-planning systems, along with the introduction of advanced applicators, real-time guidance solutions and automated afterloaders, has significantly improved procedural accuracy, comfort, and safety. The market is also being accelerated by electronic brachytherapy systems, which eliminate the logistical and regulatory challenges of using isotopes. Additionally, AI-supported dose planning, image-guided adaptive brachytherapy (IGABT), and customizable seed implants are enhancing precision and broadening the clinical applicability of brachytherapy across multiple cancer types, encouraging adoption in both developed and emerging markets.

Expanding Oncology Infrastructure and Supportive Reimbursement Policies

Growing investments in oncology infrastructure by governments, private healthcare providers and non-profit organizations especially in Asia-Pacific, Latin America and the Middle East are creating strong momentum for brachytherapy device procurement and procedural adoption. In mature markets such as North America and Western Europe, favourable reimbursement frameworks for prostate, gynecological and breast brachytherapy procedures strengthen clinical uptake, making the modality financially accessible to both providers and patients. Additionally, national cancer treatment programs, increasing penetration of specialized cancer centres, and collaborative research initiatives are collectively enhancing the availability of trained radiation oncologists and physicists, thereby enabling wider deployment of brachytherapy platforms across hospital and ambulatory settings.

Market Segmentation

• Based on the indication, the market is segmented into breast cancer, gynecological cancer, prostate cancer, skin cancer, brain cancer, and others.
• Based on the type, the market is segmented into low-dose rate and high-dose rate.

High-Dose Rate (HDR) Brachytherapy Segment to Grow at a Considerable Market Share

Among all the segments, high-dose rate (HDR) brachytherapy is expected to lead the Global Brachytherapy Market with the largest share. HDR brachytherapy is increasingly preferred because it delivers highly concentrated radiation doses in a shorter treatment time, improving patient convenience and clinical efficiency compared to Low-Dose Rate (LDR) systems. HDR solutions are widely adopted in treating various cancers including breast, prostate, gynecological, and skin cancer—due to their superior accuracy, reduced risk of radiation exposure to surrounding healthy tissues, and improved therapeutic outcomes. Furthermore, the growing availability of advanced after-loading devices, integration of real-time imaging technologies, and rising preference for outpatient procedures are accelerating the uptake of HDR brachytherapy across hospitals and specialized oncology centers. Continuous innovations, expanding reimbursement support, and increasing clinical evidence supporting HDR’s safety and effectiveness are also strengthening its dominance, making it the most influential and revenue-generating segment in the global brachytherapy market.

Breast Cancer: A Key Segment in Market Growth

Among all the indication segments, breast cancer is expected to emerge as the key segment driving market growth in the forecast period. The dominance of this segment is primarily attributed to the rising global prevalence of breast cancer, which remains the most commonly diagnosed cancer among women. Increasing awareness about early detection, availability of advanced radiotherapy solutions, and strong adoption of minimally invasive oncology treatments further accelerate demand for innovative therapeutic approaches. Technological advancements, including image-guided radiotherapy, intensity-modulated radiation therapy, and targeted molecular oncology platforms, are continuously improving survival rates and treatment precision for breast cancer patients, thereby increasing the adoption of optimized treatment plans. Additionally, government initiatives, supportive reimbursement frameworks, and expanded screening programs are strengthening patient influx for early treatment intervention across both developed and developing economies. Continuous clinical research, increasing commercial approvals of novel biologics and oncology drugs, and strong market penetration of targeted therapies further contribute to the growth momentum of this segment. Moreover, rising incidence rates in middle-aged and younger women, evolving lifestyle patterns, and accelerated availability of precision medicine are expected to reinforce this segment’s growth trajectory. Collectively, these factors position breast cancer as the most influential and fastest-growing segment within the global oncology market over the assessment period.

Regional Outlook

The global brachytherapy market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global brachytherapy market with the largest share, supported by its highly developed cancer treatment infrastructure, early adoption of advanced radiotherapy technologies and strong reimbursement systems. The country has a high prevalence of prostate, breast and gynecological cancers, which significantly increases procedural volumes for both HDR and LDR brachytherapy across hospitals and specialized oncology centres. In addition, the U.S. benefits from the presence of leading global brachytherapy manufacturers, research organizations and academic institutes that continuously contribute to technological innovation, including image-guided brachytherapy, electronic brachytherapy systems, automated afterloaders and AI-enabled treatment-planning software. The availability of skilled radiation oncologists, favourable clinical guidelines that endorse brachytherapy for several early- and intermediate-stage cancers, and extensive insurance coverage further strengthen its market leadership. Moreover, the US has a well-established regulatory pathway supporting device approvals and clinical trials, accelerating the adoption of new brachytherapy platforms and expanding implementation beyond traditional prostate applications into breast, skin and paediatric oncology. Combined with strong investments in oncology infrastructure, rising patient awareness and ongoing partnerships between hospitals and technology developers, the US is expected to sustain its dominant position in the global brachytherapy market over the coming years.

Market Players Outlook

The major companies operating in the global brachytherapy market include Becton, Dickinson and Company (BD), Eckert & Ziegler BEBIG, Elekta AB, Theragenics Corp., Varian Medical Systems, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In October 2025, ShardaCare Healthcity launched a High-Dose-Rate (HDR) Brachytherapy Unit, an advanced internal radiation therapy that utilizes tiny radioactive sources placed near tumors for targeted radiation delivery. Spearheaded by Dr. Anil Thakwani, this technology aims to provide precision-driven cancer care while minimizing harm to surrounding healthy tissues. Manufactured by Varian, the HDR technique employs a live source of Iridium-192, allowing clinicians to deliver localized doses of radiation, enhancing safety and effectiveness compared to traditional External Beam Radiotherapy.
• In March 2025, BEBIG Medical's SagiNova Brachytherapy System has launched at Father Muller Medical College Hospital (FMMCH), part of a new healthcare wing. This development coincides with the 184th anniversary of the institution's founder. The SagiNova system enhances cancer care at FMMCH by providing precise, high-dose radiation therapy at lower costs, aligning with the institution's mission of empathy and equity. BEBIG Medical aims to democratize oncology solutions globally, and with this system, FMMCH aims to strengthen its services for underserved communities.
• In January 2025, Papua New Guinea resumed radiotherapy services and initiated brachytherapy with the support of the IAEA, addressing the significant public health challenge posed by cancer, which leads to over 12,000 new cases and 7,000 deaths annually. Brachytherapy, an internal radiotherapy technique, allows high radiation doses to be delivered directly to tumors while minimizing damage to healthy tissues. This method is particularly beneficial for treating gynecological cancers and can also be applied to prostate, breast, and various other tumors.
• In April 2024, Industry and clinical collaborated has resulted in a new brachytherapy applicator for rectal cancer treatment, aimed at enhancing the precision of HDR brachytherapy delivery. Developed by Maastro radiation oncologists and physicists in partnership with Varian experts, this innovative partially 3D-printed applicator seeks to minimize the quality-of-life risks typically associated with rectal surgery.

The Report Covers

• Market value data analysis for 2026 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global brachytherapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.